SYNKAYVITE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNKAYVITE is an injectable small-molecule product approved by Roche in 1941 for an undisclosed indication. The exact mechanism of action and therapeutic target remain proprietary or legacy-classified, typical of products from this era.
LOE Approaching
Approaching loss of exclusivity signals a declining commercial opportunity with likely team consolidation or transition planning underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero active job openings linked to this product reflects its mature, declining commercial stage. Career growth on this asset is limited; professionals should expect defensive positioning or portfolio transitions.
Brand ManagerProduct Manager
Worked on SYNKAYVITE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.